2025 Press Releases 2025 2024 2023 2022 2021 Portfolio Companies New Leaf Portfolio Companies Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast CancerMay 31, 2025 Kalderos Names Healthcare Industry Veteran Daryl Todd as Chief Strategy OfficerMay 14, 2025 TigerConnect Strengthens Global Presence with New Mexico City OfficeMay 13, 2025 TigerConnect Appoints Sean O’Neal as CEO, Marking a Bold New Chapter of Innovation and GrowthMay 1, 2025 Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common StockApril 2, 2025 Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)April 2, 2025 Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT’s Predictive Power for Women’s Cardiovascular Risk at ACC.25March 31, 2025 Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical TrialMarch 11, 2025 TigerConnect to Launch Pre-Hospital and Transfer Solutions to Streamline Emergency Care Coordination and Improve Patient Throughput at HIMSS 25February 27, 2025 CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical TrialFebruary 20, 2025 Kyruus Health and aha! Announce Partnership to Enhance Patient Access and EngagementFebruary 13, 2025 Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialFebruary 11, 2025 Kyruus Health Achieves Record Growth as Searches for Care Surpass 1 BillionFebruary 5, 2025 Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular HypertensionFebruary 5, 2025 Bluesight Expands Compliance Capabilities and Strengthens Platform through Acquisition of ProtenusJanuary 9, 2025 Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)January 6, 2025
